Xovoltib 40 Mg
$195.00 – $570.00Price range: $195.00 through $570.00
Xovoltib 40 Mg is a targeted EGFR inhibitor used to treat non-small cell lung cancer by blocking cancer cell growth signals.
Description
Xovoltib 40 Mg
Xovoltib 40 Mg is a targeted anticancer medication used in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with epidermal growth factor receptor (EGFR) mutations. It contains afatinib, a second-generation tyrosine kinase inhibitor (TKI) that blocks signals responsible for cancer cell growth and proliferation. This higher-strength formulation is commonly prescribed as a standard starting dose in eligible patients. In treatment planning, intermediate doses like Xovoltib 30 Mg may be used for dose adjustment, while lower strengths such as Xovoltib 20 Mg are considered in patients requiring reduced dosing due to tolerability concerns.
Mechanism of Action
EGFR Inhibition
Xovoltib 40 Mg works by irreversibly inhibiting EGFR and related receptors involved in cancer cell growth and survival.
Targeted Antitumor Activity
By blocking these pathways, it prevents tumor cell proliferation and promotes cancer cell death. For detailed clinical insights, refer to National Cancer Institute (NCI) and for safety information, consult Mayo Clinic – Afatinib Drug Information.
Medical Uses
Xovoltib 40 Mg is used in:
- EGFR mutation-positive non-small cell lung cancer (NSCLC)
- Advanced or metastatic lung cancer
It is often prescribed as a first-line therapy in appropriate patients.
Dosage and Administration
Xovoltib 40 Mg is typically taken once daily on an empty stomach, as prescribed by an oncologist. The dosage may be adjusted based on patient response and tolerability. In clinical practice, Xovoltib 30 Mg is often used for dose reduction, while Xovoltib 20 Mg may be considered for further adjustment in patients experiencing side effects.
Clinical Effectiveness
Clinical studies have shown that afatinib significantly improves progression-free survival and disease control in patients with EGFR mutation-positive NSCLC. The 40 mg dose is widely used as a standard treatment regimen.
Safety and Side Effects
Common Side Effects
- Diarrhea
- Skin rash
- Mouth sores
- Nail changes
Serious Risks
- Severe diarrhea and dehydration
- Interstitial lung disease
- Liver toxicity
Regular monitoring is essential during therapy. For more details, refer to Mayo Clinic – Afatinib Drug Information.
Contraindications and Precautions
Xovoltib 40 Mg should be used with caution in:
- Patients with lung disorders
- Individuals with liver impairment
- Patients with gastrointestinal conditions
It should not be used during pregnancy unless prescribed by a healthcare provider.
Drug Interactions
Xovoltib 40 Mg may interact with medications affecting liver enzymes and other anticancer drugs. Patients should inform their healthcare provider about all medications they are taking. For research-based insights, refer to National Cancer Institute (NCI).
FAQs
Xovoltib 40 Mg is used to treat EGFR mutation-positive non-small cell lung cancer. It helps control tumor growth and is often prescribed as a first-line therapy in advanced or metastatic cases.
Xovoltib 40 Mg works by blocking EGFR proteins that drive cancer cell growth. This prevents cancer cells from multiplying and helps slow disease progression.
Xovoltib 40 Mg is effective but may cause side effects such as diarrhea and skin rash. Serious risks include lung inflammation and liver toxicity. Regular monitoring is required during treatment.
Xovoltib 40 Mg can interact with medications affecting liver enzymes and other drugs. Patients should inform their doctor about all medicines they are taking to ensure safe use.
The duration of treatment depends on the patient’s condition and response. It is usually taken long-term under medical supervision to maintain disease control.
